Regen BioPharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGBP research report →
About the company
Regen BioPharma, Inc. is a company dedicated to advancing regenerative medicine within the United States. It actively researches and identifies small molecule compounds designed to modulate the NR2F6 gene.
- CEO
- David Raymond Koos
- IPO
- 2014
- Employees
- 1
- HQ
- La Mesa, CA, US
Price Chart
- Market Cap
- $3.15K
- P/E
- -0.00
- P/S
- 0.01
- P/B
- -0.00
- EV/EBITDA
- -0.75
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -367.41%
- Net Margin
- -302.54%
- ROE
- 11.91%
- ROIC
- 19.75%
- Revenue
- $236.56K · 0.00%
- Net Income
- $-1,274,502 · -90.79%
- EPS
- $-0.05 · 66.13%
- Op Income
- $-338,540
- FCF YoY
- 44.66%
- 52W High
- $0.12
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 0.23
- Avg Volume
- 18.28M
Get TickerSpark's AI analysis on RGBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our RGBP coverage
Recent articles, reports, and earnings notes.
No research on RGBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RGBP report →Similar companies
Peers in the same neighborhood.